The global demand for Neuraminidase Inhibitor Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Neuraminidase inhibitors are antiviral drugs that function to block influenza virus, by preventing reproduction by budding from the host cell, limit the spread of the virus within the respiratory tract and prevent virus penetration of respiratory secretions to initiate replication. These drugs inhibit all subtypes of neuraminidase enzymes, and are effective at preventing and treating influenza, are taken within 48 hours of the onset of symptoms. Oseltamivir, zanamivir, peramivir, and zanamivir are some common examples of neuraminidase inhibitor drugs.
Growing incidence of influenza infection is driving the growth of the market. All age groups are affected each year, developing in approximately 20 % of the world's population. Neuraminidase inhibitor is recommended as a drug treatment option for COVID-19. At present, there is no vaccine or treatment for coronavirus, so identifying the drug treatment options as soon as possible is critical for the response to the COVI-19 outbreak. Neuraminidase inhibitor is discovered to have the potential antiviral treatment of human pathogen coronavirus. This brings an opportunity for growth. However, the efficacy and safety of these drugs for COVID-19 still need to be further confirmed by clinical experiments. Observational studies are still ongoing. Favourable results are expected to hold a large revenue share in the neuraminidase inhibitors market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of Neuraminidase Inhibitor.
The entire Neuraminidase Inhibitor market has been sub-categorized into drug type, route of administration, and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Drug Type
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Retail Stores
This section covers regional segmentation which accentuates on current and future demand for Neuraminidase Inhibitor market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Europe Neuraminidase Inhibitor Market By Revenue (USD MN)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Neuraminidase Inhibitor market include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, BioCryst Ltd. and Daiichi Sankyo Co. Ltd. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.